Stockreport

Kedrion Biopharma and Kamada receive FDA approval of KEDRAB for post-exposure prophylaxis against rabies infection; shares ahead 21% premarket [Seeking Alpha]

Kamada Ltd. - Ordinary Shares  (KMDA) 
Last kamada ltd. - ordinary shares earnings: 2/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: kamada.com/investors.php
PDF Kedrion Biopharma and Kamada (NASDAQ: KMDA ) announces that KEDRAB [rabies immune globulin (Human)] has received FDA approval for passive, transient post-e [Read more]